MAIA Biotechnology (MAIA) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MAIA Biotechnology (MAIA) has outperformed PMV Pharmaceuticals (PMVP) over the past year, gaining 21.7% versus a loss of 33.6%. MAIA Biotechnology is the larger company by market cap ($68.5 million vs $66.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAIA | PMVP |
|---|---|---|
| Share price | $1.11 | $0.876 |
| Market cap | $68.54M | $66.17M |
| 1-day change | -2.63% | -33.13% |
| YTD return | -27.45% | -29.92% |
| 1-year return | +21.71% | -33.64% |
| 5-year return | — | -96.22% |
| EPS (TTM) | $-0.47 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-22.40M | $-77.74M |
| 52-week high | $3.19 | $1.91 |
| 52-week low | $0.895 | $0.66 |
| Distance from 52-week high | -65.20% | -54.14% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +981.08% | +356.62% |
| Average volume | 524.29K | 787.50K |
| Shares outstanding | 61.75M | 75.53M |
| Employees | 13 | 54 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MAIA has outperformed PMVP by 55.3 percentage points over the past year.
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
MAIA vs PMVP FAQ
Which is bigger, MAIA Biotechnology or PMV Pharmaceuticals?
MAIA Biotechnology (MAIA) is larger, with a market capitalization of $68.54M compared with $66.17M for PMV Pharmaceuticals (PMVP).
Which stock has performed better over the past year, MAIA or PMVP?
MAIA returned +21.71% over the past 12 months, compared with -33.64% for PMVP (price return, excluding dividends). Past performance does not predict future results.
Are MAIA Biotechnology and PMV Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.